To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.

Enumerated powers · passes

The bill operates within the FDA's established authority to regulate interstate commerce in drugs under Article I, Section 8, Clause 3 (Commerce Clause). Requiring the FDA to provide additional information to generic drug applicants is a minor procedural addition to an existing federal regulatory scheme that has long been upheld as a valid exercise of the commerce power. It does not create new regulatory jurisdiction but merely enhances transparency within an existing, constitutionally grounded program.

Bill of Rights · passes

The bill does not implicate any provision of the Bill of Rights. It does not restrict speech, religion, assembly, press, petition, arms, quartering, search and seizure, self-incrimination, due process, takings, trial rights, or cruel and unusual punishment. It is a purely administrative disclosure requirement directed at the FDA, not at individuals or their protected activities.

Individual liberty · passes

The bill imposes no restriction on individual liberty, property, speech, labor, or belief. It only requires the FDA to provide information to drug applicants, which is a benefit to those applicants. It does not compel any individual to act or refrain from acting. The burden of any government action is on the government, and here the government is merely being asked to be more transparent in its existing regulatory decisions.

Decentralization · passes

The bill does not consolidate decision-making at a higher level of government. The FDA already has exclusive authority over generic drug approvals, and this bill merely adds a transparency requirement within that existing federal framework. It does not shift authority from individuals, local communities, or states to the federal government; it only refines how the federal government exercises its already-established authority. The four-question test is satisfied because the action is inherently federal (drug approval is a national interstate commerce matter) and does not increase centralization.

Due process and takings · passes

The bill enhances procedural fairness by requiring the FDA to explain its determinations regarding generic drug sameness, which gives applicants clearer notice of the basis for decisions. It does not deprive anyone of property without due process; rather, it provides additional information that could help applicants understand and potentially challenge adverse decisions. There is no taking of private property for public use without just compensation.